Read the latest cancer news from the National Cancer Institute. The UNM Comprehensive Cancer Center is one of only 49 NCI-designated comprehensive cancer centers bringing leading, national cancer care to New Mexico.
Since launching the Childhood Cancer Data Initiative, NCI has undertaken a range of research activities to support this important effort. In this Cancer Currents post, NCI Director Dr. Norman Sharpless provides an update on these efforts.
In a study of more than 50,000 veterans with lung cancer, those with mental illness who received mental health treatment—including for substance use—lived substantially longer than those who didn’t participate in such programs.
FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.
For children with aggressive Burkitt lymphoma and other B-cell non-Hodgkin lymphomas, adding rituximab (Rituxan, Truxima) to chemotherapy substantially increases the likelihood of the child being cured, results from a large clinical trial show.
In response to the COVID-19 pandemic, cancer researchers are making changes to clinical trials to ensure patient safety and protect the integrity of their work. Some changes, such as greater use of telemedicine, will likely continue into the future.
Results from a large study show that, for most people with advanced bladder cancer, starting immunotherapy with avelumab (Bavencio) shortly after initial treatment with chemotherapy is better than delaying treatment.
FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.
FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. The PARP inhibitors are approved for men whose cancers have stopped responding to hormone treatment and have specific genetic alterations.